Kogenix Therapeutics, Inc. is a pre-clinical stage gene therapy startup company developing novel treatments for neurodegenerative diseases. The company’s therapeutic strategy is based on increasing the level of Klotho protein in the brain, using adeno-associated virus vectors (AAV) as the delivery mechanism for the Klotho gene. Kogenix has obtained an exclusive license to intellectual property, covered in a recent patent application, from an academic institution. Our scientific founders have deep expertise and over 80 years of combined experience in neuroscience and gene therapy. Kogenix, headquartered in Boston, has strong scientific ties and collaborations with Universitat Autonoma de Barcelona and its gene therapy viral vector production unit, as well as the Boston University School of Medicine. Our pre-clinical programs include: (i) a neuroprotective Klotho gene therapy for Alzheimer’s disease and (ii) a re-myelination inducing Klotho gene therapy for Multiple Sclerosis.

AAV is an effective and safe gene therapy delivery mechanism into the central nervous system (CNS), using a virus not currently known to cause diseases. The effects are long lasting and therefore gene therapy has the additional potential benefit of a one-time single dose treatment. The progress made in recent years in manufacturing, scaling up of volumes and quality control, make this gene therapy approach commercially viable. Several CNS gene therapies are currently in clinical trials. Over $1 Billion has been invested in gene therapy companies in the last four years.


Assumpció Bosch

– Associate Professor of Biochemistry and Molecular Biology at Universitat Autonoma de Barcelona (UAB)
– 23 years of research experience in gene therapy strategies in the CNS
– Dr. Bosch holds a Ph.D. in Biological Sciences from University of Barcelona

Miguel Chillon

– ICREA (Catalan Institution for Research and Advanced Studies) senior researcher at the Vall d’Hebron Research Institute (VHIR) and at the Institute of Neurosciences of the Universitat Autonoma de Barcelona (UAB)
– Director of the Viral Vector Production Unit (VHIR/UAB)
– Founder of Nanotherapix
– 23 years of experience in gene therapy strategies using viral vectors in vivo models of human diseases
– Dr. Chillon holds a Ph.D. in Biological Sciences from University of Barcelona

Carmela Abraham

– Professor of Biochemistry, Pharmacology and Experimental Therapeutics at Boston University School of Medicine (BU)
– 36 years of research experience including Alzheimer’s disease, normal aging of the brain, myelin biology, and neuroinflammation
– Founder of Klogene Therapeutics, Inc.
– Dr. Abraham holds a Ph.D. in Neuroscience from Harvard University

Menachem Abraham

– Thirty three years of entrepreneurial and executive leadership experience (private and publicly traded companies) including Founder and CEO of high-tech and biotech companies
– Served as Director on the boards of over a dozen private and public companies
– Transitioned from high-tech to biotech starting in 2013
– Bachelor’s and master’s degrees in electrical engineering from the Technion – Israel Institute of Technology

Management and Board of Directors